AstraZeneca unveils promising anti-obesity drug
AstraZeneca has launched a new drug from the GLP-1 class to combat obesity. A study involving 310 individuals showed that the medication, called EligoGliberon, taken once daily orally, produces results similar to other drugs in the same class in reducing appetite and promoting weight loss. The results are promising; however, there is still a need for larger clinical trials to confirm long-term safety and effectiveness before applying for marketing approval.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)